Eli Lilly treatment solanezumab failed to slow disease
Solanezumab’s failure is a blow to efforts to treat Alzheimer’s in people who are in the very early stage of the disease and have not yet shown clinical study enrolled more than 1,000 seniors who had normal memory and…
Read More